Filtered By:
Specialty: Hematology
Condition: Thrombosis
This page shows you your search results in order of date. This is page number 11.
Order by Relevance | Date
Total 1625 results found since Jan 2013.
A Review of FXIa Inhibition as a Novel Target for Anticoagulation
Hamostaseologie. 2023 Feb;43(1):28-36. doi: 10.1055/a-1984-7021. Epub 2023 Feb 20.ABSTRACTLimitations of vitamin K antagonists as chronic oral anticoagulant therapy have largely been supplanted by direct factor IIa and factor Xa inhibitor oral anticoagulants with similar efficacy but an overall better safety profile, lack of routine monitoring, and very limited drug-drug interactions compared with agents such as warfarin. However, an increased risk of bleeding remains even with these new-generation oral anticoagulants in fragile patient populations, in patients requiring dual or triple antithrombotic therapy, or high bleed...
Source: Hamostaseologie - February 22, 2023 Category: Hematology Authors: Ioannis Koulas Alex C Spyropoulos Source Type: research
D-dimer and the risk of hypertension: The REasons for Geographic And Racial Differences in Stroke Cohort Study
CONCLUSION: D-dimer concentration reflects pathophysiology related to the development of hypertension. Specific mechanisms require further study and may involve adiposity.PMID:36760775 | PMC:PMC9903654 | DOI:10.1016/j.rpth.2022.100016
Source: Thrombosis and Haemostasis - February 10, 2023 Category: Hematology Authors: Debora Kamin Mukaz Boyi Guo D Leann Long Suzanne E Judd Timothy B Plante Leslie A McClure Alisa S Wolberg Neil A Zakai George Howard Mary Cushman Source Type: research
Recurrent thrombotic events after disappearance of antiphospholipid autoantibodies: A long-term longitudinal study in patients with antiphospholipid syndrome
Antiphospholipid syndrome (APS) is an autoimmune disease characterized by the occurrence of thrombosis and/or pregnancy morbidity related to the presence of persistent antiphospholipid autoantibodies (aPL) [1]. The most frequent clinical manifestations of APS are thrombotic events and death may be caused by stroke, myocardial infarction, pulmonary embolism or catastrophic APS [2]. APS treatment is based on long term anticoagulation [3].
Source: Thrombosis Research - February 9, 2023 Category: Hematology Authors: Thomas Ballul, Arthur Mageau, Pascale Roland Nicaise, Nadine Ajzenberg, Andrey Strukov, Antoine Dossier, Diane Rouzaud, Thomas Papo, Karim Sacr é Tags: Letter to the Editors-in-Chief Source Type: research
Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke
Conclusion: Reversal of dabigatran with idarucizumab in stroke patients appears easy to manage, safe and beneficial. The SOPs aim to reassure stroke physicians to include dabigatran reversal into their daily clinical routine when dealing with patients presenting with ischemic or hemorrhagic stroke under dabigatran therapy.
Source: Journal of Thrombosis and Thrombolysis - February 4, 2023 Category: Hematology Source Type: research
Dilemmas in hematology: consults in patients with arterial thrombosis
J Thromb Haemost. 2023 Jan 10:S1538-7836(23)00030-2. doi: 10.1016/j.jtha.2023.01.002. Online ahead of print.ABSTRACTArterial thrombotic events, particularly ischemic stroke and myocardial infarction, are common, and mostly occur due to atherosclerotic disease or arrhythmias. The diagnosis and management of the majority of such events occurs without the involvement of a hematologist, following established guidelines or pathways. In this review, we discuss 3 scenarios in which optimal management is less certain. These scenarios concern patients with a left ventricular thrombus, in whom the duration and choice of anticoagulan...
Source: Thrombosis and Haemostasis - January 25, 2023 Category: Hematology Authors: Dawn Swan Jean M Connors Jecko Thachil Source Type: research
Letter to the Editor Re “Endovascular thrombectomy or bridging therapy in minor ischemic stroke with large vessel occlusion”
We commend Tu et al. on the recent article on comparison of endovascular thrombectomy (EVT) versus bridging therapy (BT) in minor stroke patients with large vessel occlusion (LVO) [1]. Based on retrospective, observational study of 903 patients, the authors conclude non-inferiority of EVT compared to BT in patients presenting within 4.5 h of onset. We have a few questions and comments.
Source: Thrombosis Research - January 24, 2023 Category: Hematology Authors: Ajay Malhotra, Mihir Khunte, Xiao Wu, Mahla Radmard Tags: Letter to the Editors-in-Chief Source Type: research
A response to a letter to the editor TR-D-22-00887
In this study, we found that among patients with minor acute ischemic stroke due to large vessel occlusions (AIS-LVO), direct endovascular thrombectomy (EVT), compared with bridging therapy, met the prespecified statistical threshold for noninferiority for the 3-month prognosis [1].
Source: Thrombosis Research - January 16, 2023 Category: Hematology Authors: Wen-Jun Tu, Yicheng Xu Tags: Letter to the Editors-in-Chief Source Type: research
Post-PCI Risk Assessment by Inflammation Activity According to Disease Acuity and Time from Procedure
CONCLUSION: AMI patients have greater inflammation during the early and late phases than non-AMI patients. Risk phenotype of hsCRPbaseline correlates with 1-month outcomes only in AMI patients. Whereas the prognostic implication of this risk phenotype appears similar during the late phase, irrespective of the disease acuity.PMID:36634702 | DOI:10.1055/a-2011-8426
Source: Thrombosis and Haemostasis - January 12, 2023 Category: Hematology Authors: Haegeun Song Jong-Hwa Ahn Min Gyu Kang Kye Hwan Kim Jae Seok Bae Sang-Yeong Cho Jin Sin Koh Yongwhi Park Seok-Jae Hwang Eun Jeong Cho Kyeongmin Byeon Sang-Wook Kim Udaya S Tantry Paul A Gurbel Jin-Yong Hwang Young-Hoon Jeong Source Type: research
Stroke and myocardial infarction in patients with abdominal aortic aneurysms and new-onset atrial fibrillation
Conclusion Cardiovascular prognosis has improved in patients with prevalent AAA disease and new-onset AF in concordance with optimization of antithrombotic therapy over time. A diagnosis of AF conferred residual risk of stroke and myocardial infarction.PMID:36626930 | DOI:10.1055/a-2009-8954
Source: Thrombosis and Haemostasis - January 10, 2023 Category: Hematology Authors: Chalotte Winther Winther Nicolajsen Peter Br ønnum Nielsen Martin Jensen Nikolaj Eldrup Torben Bjerregaard Larsen Gregory Yh Lip Samuel Z Goldhaber Mette S øgaard Source Type: research
Stroke mortality in cancer survivors: A population-based study in Japan
The association between cancer survivors and stroke deaths remains unclear. We aimed to evaluate the risk of fatal stroke in patients with cancer.
Source: Thrombosis Research - January 9, 2023 Category: Hematology Authors: Yasufumi Gon, Ling Zha, Tsutomu Sasaki, Toshitaka Morishima, Yuko Ohno, Hideki Mochizuki, Tomotaka Sobue, Isao Miyashiro Source Type: research
Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation
The objective of this study was to compare effectiveness and safety between reduced dose DOACs and high TTR warfarin treatment (TTR ≥ 70%) in NVAF. A Swedish anticoagulation registry was used in identifying eligible patients from July 2011 to December 2017. The study cohort consisted of 40,564 patients with newly initiated DOAC (apixaban, dabigatran, or rivaroxaban) (11,083 patients) or warfarin treatment (29,481 patients ) after exclusion of 374,135 patients due to not being warfarin or DOAC naïve, not being prescribed reduced dose, having previous mechanical heart valve (MHV), or being under 18 years old. The me...
Source: Journal of Thrombosis and Thrombolysis - January 6, 2023 Category: Hematology Source Type: research
Impact of stroke on survival in patients with cancer
Thromboembolic events, including venous thromboembolism (VTE) and arterial thromboembolism (ATE), are significant concerns for patients with cancer as they can interrupt or delay essential cancer treatments and worsen outcomes [1]. Previous studies have suggested that VTE is associated with an increased risk of mortality in patients with cancer [2 –5]. Meanwhile, few studies have investigated the relationship between ATE and outcomes in patients with cancer. Grilz et al. assessed the effect of ATE on 2-year survival in such patients and reported that ATE was associated with a 3.2-fold increased risk of all-cause mortality [6].
Source: Thrombosis Research - January 6, 2023 Category: Hematology Authors: Yasufumi Gon, Tsutomu Sasaki, Tomohiro Kawano, Shuhei Okazaki, Kenichi Todo, Toshihiro Takeda, Yasushi Matsumura, Hideki Mochizuki Tags: Letter to the Editors-in-Chief Source Type: research
